Clinical study
Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection
| Status | Not yet recruiting |
|---|---|
| Type | Individual-case protocol |
| Countries | Location not listed |
| Conditions studied | Mycobacterium Abscessus Infection; Bacteriophage Therapy; Pulmonary Disease |
| Study years | 2026 (estimated)–2028 (estimated) |
| Entry review | 2026-10-03 |
Participation
Check the study record or contact the study team for current recruitment and eligibility.
Study eligibility
Inclusion Criteria: * Consent to participation Exclusion Criteria: * non-consent to participation
Study description
The objective of this study is to evaluate mycobacteriophage therapy using in-vitro validated mycobacteriophage DP-QB-MYA-002 in combination with conventional antimycobacterial agents for the treatment of multidrug-resistant Mycobacterium abscessus pulmonary disease, with the goal of reducing mycobacterial burden and improving pulmonary outcomes.
Study registrations
| ClinicalTrials.gov | NCT07429162 |
|---|
Notes from the source review
- Single-patient protocol (target/actual n=1); not a broad recruiting program.
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Study ID | nct07429162 |
|---|